Capsaicin receptor antagonists: A promising new addition to the pain clinic

British Journal of Anaesthesia

Volumn 102, Issue 2, 2009, Pages 153-155

  Lambert, D G ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 BROMOPHENYL) 3 [1 (5 TRIFLUOROMETHYL 2 PYRIDINYL) 3 PYRROLIDINYL]UREA; 4 CHLORO N (3 METHOXYPHENYL)CINNAMAMIDE; AZD 1386; BRADYKININ; CAPSAICIN; GRC 6211; MORPHINE; NGD 8243; PROSTAGLANDIN; RESINIFERATOXIN; SB 782443; UNCLASSIFIED DRUG; VANILLOID RECEPTOR; VANILLOID RECEPTOR 1;

ANTINOCICEPTION; CALCIUM TRANSPORT; CONTACT DERMATITIS; DIZZINESS; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG RECEPTOR BINDING; EDITORIAL; HEADACHE; HUMAN; PAIN; PRIORITY JOURNAL; SINGLE DRUG DOSE;

EID: 58449090339     PISSN: 00070912     EISSN: 14716771     Source Type: Journal    
DOI: 10.1093/bja/aen354     Document Type: Editorial

References (23)

1. Szallasi A, Blumberg PM. Vanilloid (Capsaicin) receptors and mechanisms. Pharmacol Rev 1999; 51: 159-212
2. Tominaga M, Tominaga T. Structure and function of TRPV1. Pflugers Arch 2005; 451: 143-50
3. Szallasi A. Small molecule vanilloid TRPV1 receptor antagonists approaching drug status: can they live up to the expectations? Naunyn Schmiedebergs Arch Pharmacol 2006; 373: 273-86
4. Szallasi A, Cruz F, Geppetti P. TRPV1: a therapeutic target for novel analgesic drugs? Trends Mol Med 2006; 12: 545-54
5. Szallasi A, Cortright DN, Blum CA, Eid SR. The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept. Nat Rev Drug Discov 2007; 6: 357-72
6. Cortright DN, Szallasi A. Biochemical pharmacology of the vanilloid receptor TRPV1. An update. Eur J Biochem 2004; 271: 1814-9
7. Zhang WY, Li Wan Po A. The effectiveness of topically applied capsaicin. A meta-analysis. Eur J Clin Pharmacol 1994; 46: 517-22
8. Available from www.medicine.ox.ac.uk/bandolier/band29/b29-6.html
9. Wilson-Gerwing TD, Dmyterko MV, Zochodne DW, Johnston JM, Verge VM. Neurotrophin-3 suppresses thermal hyperalgesia associated with neuropathic pain and attenuates transient receptor potential vanilloid receptor-1 expression in adult sensory neurons. J Neurosci 2005; 25: 758-67
10. Fernihough J, Gentry C, Bevan S, Winter J. Regulation of calcitonin gene-related peptide and TRPV1 in a rat model of osteoarthritis. Neurosci Lett 2005; 388: 75-80
11. Barton NJ, McQueen DS, Thomson D, et al. Attenuation of experimental arthritis in TRPV1R knockout mice. Exp Mol Pathol 2006; 81: 166-70
12. Morgan CR, Rodd HD, Clayton N, Davis JB, Boissonade FM. Vanilloid receptor 1 expression in human tooth pulp in relation to caries and pain. J Orofac Pain 2005; 19: 248-60
13. Niiyama Y, Kawamata T, Yamamoto J, Furuse S, Namiki A. SB366791, a TRPV1 antagonist, potentiates analgesic effects of systemic morphine in a murine model of bone cancer pain. Br J Anaesth 2009; 102: 251-8
14. Yamamoto J, Kawamata T, Niiyama Y, Omote K, Namiki A. Down-regulation of mu opioid receptor expression within distinct subpopulations of dorsal root ganglion neurons in a murine model of bone cancer pain. Neuroscience 2008; 151: 65-72
15. Niiyama Y, Kawamata T, Yamamoto J, Omote K, Namiki A. Bone cancer increases transient receptor potential vanilloid subfamily 1 expression within distinct subpopulations of dorsal root ganglion neurons. Neuroscience 2007; 148: 560-72
16. Gunthorpe MJ, Hannan SL, Smart D, et al. Characterization of SB-705498, a potent and selective vanilloid receptor-1 (VR1/ TRPV1) antagonist that inhibits the capsaicin-, acid-, and heat-mediated activation of the receptor. J Pharmacol Exp Ther 2007; 321: 1183-92
17. Rami HK, Thompson M, Stemp G, et al. Discovery of SB-705498: a potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development. Bioorg Med Chem Lett 2006; 16: 3287-91
18. Chizh BA, O'Donnell MB, Napolitano A, et al. The effects of the TRPV1 antagonist SB-705498 on TRPV1 receptor-mediated activity and inflammatory hyperalgesia in humans. Pain 2007; 132: 132-41
19. Available from http://gsk-clinicalstudyregister.com/protocolcomp-list. jsp?compound=Sb705498&studyType=All&phase=All&population= All&marketing=All&status=All&country=All
20. Westaway SM, Thompson M, Rami HK, et al. Design and synthesis of 6-phenylnicotinamide derivatives as antagonists of TRPV1. Bioorg Med Chem Lett 2008; 18: 5609-13
21. Available from http://www.glenmarkpharma.com/research/clinical.html
22. Available from http://www.astrazeneca.com/article/511390.aspx
23. Available from http://www.neurogen.com/products/vr1index.htm